biotech / news / / Benzinga
The Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model and the Global Benchmark for Efficient Drug Pricing (GLOBE) Model would require manufacturer rebates.
CMS proposed two mandatory models, GUARD and GLOBE, to tie Medicare drug prices to international benchmarks.
KEY POINTS
- GUARD targets Medicare Part D drugs and would require manufacturer rebates when U.S. prices exceed international prices.
- GLOBE would apply similar international price benchmarking to select Medicare Part B drugs starting October 1, 2026.
- Both models will use manufacturer-reported international pricing data to determine required rebate amounts.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →